$SRPT — FinTwit mentions on Surfaced

$SRPT — FinTwit mentions on Surfaced

Recent calls

24 calls

@adamfeuersteinMay 14, 2026 · 11:07 AM

$RGNX Duchenne gene therapy study results are out: microdystrophin expression reached an average of 71% of normal across all 31 boys at 12 wks. Functional improvements in a subset of boys followed for one year also seen. The big question remains: Will the FDA still follow the $SRPT precedent and grant accelerated approval to the Regenxbio gene therapy? CEO Curran Simpson told me the company is holding off on submitting to the FDA until early next year. “I think our data checks every single box that you would want for accelerated approval,” he told me. "We’re not in a rush to go to the FDA at this point. We want to give time for the leadership changes to occur. But that’s OK, because we can still meet our timeline of securing an approval in 2027." More details in our story, written with @Jasonmmast in the following post.

@adamfeuersteinApr 16, 2026 · 11:25 AM

Roche to launch another Elevidys trial, with eyes on European approval https://t.co/eAANNiihpt via @DrewQJoseph $SRPT

@adamfeuersteinMar 25, 2026 · 2:30 PM

Sarepta Therapeutics $SRPT shares rise on early promise for rare disease drugs. New results from small studies could support the beleaguered company’s pivot. https://t.co/fRuvcTmt0i via @damiangarde

@adamfeuersteinFeb 26, 2026 · 12:42 AM

$SRPT Sarepta Therapeutics CEO Doug Ingram will retire after a tumultuous decade https://t.co/EBnOUKSLJg via @Jasonmmast

@adamfeuersteinFeb 25, 2026 · 11:06 PM

$SRPT CEO Doug Ingram is out https://t.co/0IAMBkji3d

@adamfeuersteinDec 17, 2025 · 1:51 PM

The Worst Biopharma CEO of 2025 made decisions with tragic consequences Doug Ingram, Sarepta Therapeutics. $SRPT Is anyone surprised? Does anyone disagree? https://t.co/1I7VrJFzpC

@adamfeuersteinDec 8, 2025 · 11:37 AM

$DYN Dyne Therapeutics plans to file for approval for next-generation Duchenne drug. The medicine could be a more effective version of controversial Sarepta $SRPT drug https://t.co/BBGe0cju3l via @Jasonmmast

@adamfeuersteinNov 18, 2025 · 3:30 PM

FDA’s stronger warning on Sarepta $SRPT gene therapy raises new questions about heart risk https://t.co/xY4146JVTI via @Jasonmmast and me

@adamfeuersteinNov 14, 2025 · 7:00 PM

$SRPT New Elevidys label https://t.co/N0eknOP1aR

@adamfeuersteinNov 6, 2025 · 2:27 PM

Lastly, I revisited $SRPT and the absurd claim of a "positive trend" for Amondys and Vyondys. The treatment difference between Amondys and Vyondys, Sarepta’s exon-skipping drugs, and a placebo was six-hundredths of a step per second on a timed test that asked patients to walk up a flight of four stairs. 0.06 steps/second is a meaningful improvement in velocity if you’re an elite swimmer or runner training for the Olympics. For boys with Duchenne — or for any person going about their day — it’s imperceptible and totally meaningless.

@adamfeuersteinNov 4, 2025 · 12:50 PM

Sarepta’s $SRPT dismal quarter marred by drug failures and a long list of excuses https://t.co/FZor1xE0Ap

@adamfeuersteinNov 3, 2025 · 9:34 PM

$SRPT - CEO Doug Ingram is very good at making excuses for why ph3/confirmatory studies fail.

@adamfeuersteinOct 10, 2025 · 10:00 PM

Sarepta $SRPT to seek approval for gene therapy in rare form of muscular dystrophy “The company has said it plans to file for approval in the disease, known as limb girdle muscular dystrophy (LGMD) 2E. That would make it the first approved treatment in LGMD, a broad collection of highly rare diseases that can deprive patients of the ability to walk and in some case shorten life. But it is likely to face a significant uphill battle. “ https://t.co/BVIUZUfeuF via @Jasonmmast

@adamfeuersteinOct 8, 2025 · 10:27 AM

$SRPT Sarepta suffers a setback as N.Y. panel recommends state Medicaid pause coverage of Duchenne gene therapy Elevidys https://t.co/8f1N0ugfLf via @pharmalot

@adamfeuersteinAug 25, 2025 · 9:06 PM

@Alpha_bro1 @MattB79569101 @commonsenseplay @Sanctuary_Bio The FDA approved Elevidys despite the failure of its clinical trial. Secondary endpoints can’t “succeed” if the primary endpoint fails. The FDA did not set the primary endpoint of the Elevidys study. $SRPT did. Sarepta was confident NSAA at 1 year would be enough to prove Elevidys benefit based on lessons learned from the prior studies. Sarepta was wrong. Do you honestly not know any of this, or are you just shit posting?

@adamfeuersteinAug 24, 2025 · 2:16 PM

@matthewherper @BiotechObserver @john_hersc79276 @Biohazard3737 More excuses and gaslighting from the $SRPT cult. 6MWT was the best endpoint, until it wasn't. NSAA was the best endpoint, until it wasn't. Now, time to rise is the best endpoint?

@adamfeuersteinAug 21, 2025 · 2:25 PM

@Biohazard3737 Couple of responses: "If Elevidys is disease modifying..." This gets to the root of all $SRPT criticism, legitimately. The company has never conducted a successful clinical trial - meaning demonstrably proven any of its drugs/gene therapies are effective or beneficial for patients. That's a tremendous problem that should never be ignored. What is the acceptable death rate? That's a great question. I don't know. I'd like $SRPT or those who think deaths don't matter to provide an answer. There will be more Elevidys-related deaths, including in ambulatory patients. I agree. Tragically. So, what will the FDA do when it happens?

@adamfeuersteinJul 28, 2025 · 8:59 PM

Another twist... FDA permits use of Sarepta Therapeutics’ $SRPT Duchenne therapy in younger patients after short-lived halt https://t.co/AAZpW30smm

@adamfeuersteinJul 25, 2025 · 1:36 PM

Amazing to watch anonymous cowardly trolls (not you, @PCM_bio ) criticize STAT for negative bias against $SRPT and then when we bring a Duchenne mother’s voice DIRECTLY to listeners, we’re also scheming somehow. The case exemplified by Kaylen, the mom we spoke with on the podcast, is not an anomaly. I’ll correct you here, Thomas. Yes, liver problems are a known risk factor, but the rate and severity in the real world setting are under-reported. Sarepta will not disclose hospitalization rates, despite being asked repeatedly. Regulators are very concerned, and it’s a key reason behind the actions taken over the past 2 weeks.

@adamfeuersteinJul 24, 2025 · 12:35 PM

This week's Biotech Scorecard digs deeper into the Sarepta $SRPT #Duchenne gene therapy debacle. 1. Sarepta may not survive. If Elevidys cannot return to the market (and STAT's reporting this week suggests it will not) the company is facing a severe cash flow and debt crisis. I dig deeper into the numbers. 2. Putting business and stock prices aside, this week has been wrenching for Duchenne families. On this week's Readout LOUD podcast, we spoke with the mother of a boy who was treated with Elevidys. She wants Sarepta and the FDA to reach an agreement that returns Elevidys to the market. Listen when the episode drops tonight. 3. What happens to Doug Ingram? His future as CEO hinges on two of the eight Sarepta board members, including investor Rick Barry. Remember him? Yes, he's the $SAVA guy, too. I take a closer look at some weird Sarepta board dynamics. Want to read more? The web edition of this week's newsletter can be read at the link below.

@adamfeuersteinJul 22, 2025 · 12:59 AM

$SRPT With Elevidys paused, risk to balance sheet and solvency is an issue again. Obviously, will depend on how long Elevidys remains off the market, and whether Sarepta can restructure debt if necessary.

@adamfeuersteinJul 21, 2025 · 11:45 PM

$SRPT just announced pause to all Elevidys shipments in the US.

@adamfeuersteinJul 18, 2025 · 11:54 PM

UPDATED:. Sarepta Therapeutics $SRPT crisis is huge blow to Duchenne families, company Company has refused FDA request that it pull gene therapy from the market following patient deaths https://t.co/TH7rjarWHv

@adamfeuersteinJul 16, 2025 · 8:19 PM

Now official and then some... Sarepta Therapeutics $SRPT lays off one-third of workforce in drastic cost-cutting move https://t.co/Bv9otdq2b9 w/ @Jasonmmast